Welcome to our dedicated page for Donaldson Company news (Ticker: $DCI), a resource for investors and traders seeking the latest updates and insights on Donaldson Company stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Donaldson Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Donaldson Company's position in the market.
Donaldson Company, Inc. (NYSE: DCI) will present at the Oppenheimer 19th Annual Industrial Growth Conference on May 6, 2024. The CFO, Scott Robinson, will represent the company at 12:00 p.m. ET. The presentation can be accessed via live webcast on the company's Investor Relations website. Donaldson is a technology-led filtration products provider, serving various industries globally.
Donaldson Company, Inc. (NYSE: DCI) will webcast its third-quarter 2024 earnings conference call on June 4, 2024, at 9:00 a.m. CT. The webcast replay will be available on the company's Investor Relations website. Donaldson, founded in 1915, is a global leader in filtration products serving various industries.
Donaldson Company, a leading provider of filtration products, announced acquiring a 49% stake in Medica S.p.A., a leader in hollow fiber membrane filtration technology. Medica, generating €80 million in revenue in 2023, specializes in blood purification and water purification products. The acquisition is pending the outcome of a tender offer and is expected to be completed by Q3 2024.
